Keywords: FODMAP; NCGS; Wheat; Intestine; Challenge; ATI; α-amylase trypsin inhibitor; DBPCFC; double-blind placebo-controlled food challenge; FODMAPs; fermentable oligo-, di-, monosaccharides and polyols; GSRS-IBS; gastrointestinal symptom rating scale irritable
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Diet adherence; Celiac disease; Non-celiac gluten sensitivity; Gluten exposure; Gluten contamination; ATI; amylase-trypsin inhibitor; BMI; body mass index; BMR; basal metabolic rate; BMR-factor; energy intake and basal metabolic rate-ratio; CD; coeliac di
Keywords: BMSCs; bone marrow mesenchymal stem cells; AECs; alveolar epithelial cells; ATI; alveolar epithelial type I; ATII; alveolar epithelial type II; FN; fibronectin; SP-C; surfactant protein-C; AQP-5; aquaporin-5; HGF; hepatocyte growth factor; KGF; keratinocy
Keywords: CD; Immunogenicity; Monitoring Therapy; Ulcerative Colitis; ATI; antibodies to infliximab; CD; Crohn's disease; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; HMSA; homogeneous mobility shift assay; HR; hazard ratio; IBD; inflammator
Keywords: ATI; 4-Amino-2,2,5,5-tetramethyl-2,5-dihydro-1H-imidazol-1-oxyl; CBC; Calvin-Benson cycle; EPR; Electron paramagnetic resonance; ETC; Electron transport chain; MV; Methyl viologen; PQH2 and PQ; Plastoquinol and plastoquinone, respectively; Pc; Plastocya
Keywords: AFM; Atomic Force Microscopy; ARDS; Acute Respiratory Distress Syndrome; ATI; Alveolar Type I (cell); ATII; Alveolar Type II (cell); CBS; Captive Bubble Surfactometer; CPAP; Continuous Positive Airway Pressure; CRP; C-reactive Protein; DPPC; Dipalmitoylph
Keywords: APIs; Active Pharmaceutical Ingredients; AD; applicability domain; ATI; Aquatic Toxicity Index; PBT; Persistence, Bioaccumulation and Toxicity; CAS; Chemical Abstract Service; CCC; concordance correlation coefficient; CEC; Contaminants of Emerging Concern
Keywords: Coeliac disease; Gluten; Non-coeliac gluten sensitivity; Wheat allergy; ATI; amylase trypsin inhibitor; CD; coeliac disease; CU; contact urticaria; DH; dermatitis herpetiformis; ESPGHAN; European Society for Pediatric Gastroenterology, Hepatology and Nutr
Keywords: Ca2+ channel; K+ channel; Ca2+-activated Clâ channel; Transcription; Pre-mRNA splicing; Protein degradation; AD; Alzheimer's disease; ADPR; ADP ribose; AITC; allyl isothiocyanate; AKAP; A-kinase anchoring protein; AMPK; 5â² AMP-activated protein kinase
Keywords: ATI; Amylase/trypsin inhibitor; CD; Celiac disease; FODMAP; Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBS; Irritable bowel syndrome; NCGS; Nonceliac gluten sensitivity;
Keywords: Adaptive; Allergy; ATI; Barley; CNS; Dendritic cell; Extraintestinal; Gliadin; Intestine; Macrophage; Monocyte; Rye
Keywords: CD; Crohn's disease; Anti-TNF-α; anti-tumor necrosis factor-α; IFX; infliximab; PCDAI; Pediatric Crohn's Disease Activity Index; ATI; anti-infliximab-antibodies; PDAI; Perianal Crohn's Disease Activity Index; QoL; quality of life; UC; ulcerative colitis
Keywords: ATI; Absolute total immature neutrophils; ATN; Absolute total neutrophils; AUC; Area under the curve; CBC; Complete blood count; EOS; Early-onset sepsis; GBS; Group B streptococcal; I:T; Immature to total neutrophil proportion or ratio; NICU; Neonatal int
Keywords: Remicade; Drug Holiday; Antidrug Antibody; Pharmacokinetics; ATI; antibodies to infliximab; CI; confidence interval; CRP; C-reactive protein; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IMM; immunomodulator; IR; infusion reaction;
Keywords: AGM; abnormal glucose metabolism; DM; diabetes mellitus; preDM; prediabetes; IGT; impaired glucose tolerance; IFG; impaired fasting glucose; NGT; normal glucose tolerance; END; early neurological deterioration; RS; in-hospital recurrence of stroke; OGTT;
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Keywords: Endoscopic; TNF Antagonist; Therapeutic Drug Monitoring; Optimization; ATI; antibody to infliximab; CD; Crohn's disease; IBD; inflammatory bowel disease; IQR; interquartile range; TAXIT; Trough Concentration Adapted Infliximab Treatment; TDM; therapeuti
WNT receptor signalling in lung physiology and pathology
Keywords: ABC; active β-catenin/non-phosphorylated β-catenin; APC; adenomatous polyposis coli; ATI; alveolar epithelial type I cell; ATII; alveolar epithelial type II cell; AXIN; axis inhibition protein; CBR2; carbonyl reductase 2; CK1; casein kinase 1; CELSR1; c
Mode, technology, energy consumption, and resulting CO2 emissions in China's transport sector up to 2050
Keywords: AAGR; Average annual growth rate; ATI; Additional tax increase; CNG; Compressed natural gas; CPR; Comprehensive; DCM; Discrete-choice method; ECM; Energy and CO2 emissions module; EEI; Energy efficiency improvement; EVs; Electric vehicles; GDP; Gross dome
Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double-Blind, Placebo-Controlled Trials
Keywords: Celiac Disease; Wheat Allergy; Irritable Bowel Syndrome; Gluten-Free Diet; ATI; amylase-trypsin inhibitor; DBPC; double-blind placebo-controlled; FODMAP; fermentable oligosaccharides, di-, monosaccharides and polyols; IBS; irritable bowel syndrome; NCGS;
Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis
Keywords: ACE2; angiotensin I converting enzyme 2; AGT; angiotensinogen; ATI; alveolar epithelial cells type I; ATII; alveolar epithelial cells type II; BALF; bronchial alveolar lavage fluid; BMP2; bone morphogenetic protein 2; BMPR1A; bone morphogenetic protein re
Comparison of infliximab drug measurement across three commercially available ELISA kits
Keywords: Infliximab; antibodies to infliximab; ATI; therapeutic drug monitoring;
Original ResearchFull Report: Clinical-Alimentary TractInfliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection
Keywords: PREVENT; Anti-TNF; Inflammatory Bowel Disease; CDAI; ARR; absolute risk reduction; ATI; antibodies to infliximab; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CI; confidence interval; TNF; tumor necrosis factor;
Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis
Keywords: alveolar type II cells; cell therapy; idiopathic pulmonary fibrosis; 6MWT; 6-min walk test; ATI; alveolar type I; ATII; alveolar type II; Dlco; single-breath diffusing capacity for carbon monoxide; HRCT; high-resolution computed tomography; IPF; idiopathi
Nonceliac Gluten Sensitivity
Keywords: Allergy; Celiac Disease; FODMAP; Food; Gluten; IBS; Sensitivity; Wheat; ATI; amylase trypsin inhibitor; FODMAPs; fermentable oligo- and disacchararides; GFD; gluten-free diet; GI; gastrointestinal; IBS; irritable bowel syndrome; IL; interleukin; NCGS; non
Original articleAlimentary tractFactors Associated With Short- and Long-Term Outcomes of Therapy for Crohn's Disease
Keywords: SONIC; Anti-TNF Agent; Tumor Necrosis Factor; Drug; ÎCRP26; change in C-reactive protein level from baseline at week 26; ATI; antibodies to infliximab; AUC; area under the curve; CD; Crohn's disease; CDEIS; Crohn's disease endoscopic index score; CI;
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Keywords: Monoclonal Antibody; Personalized Medicine; Pharmacokinetics; Therapeutic Drug Monitoring; ATI; antibodies to infliximab; CD; Crohn's disease; CRP; C-reactive protein; HBI; Harvey-Bradshaw Index; IBD; inflammatory bowel disease; IQR; interquartile range
Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
Keywords: Anti-Tumor Necrosis Factor; Inflammatory Bowel Disease; Anti-TNF Agent; Serology; Prognosis; VCAM; ASCA; anti-Saccharomyces cerevisiae antibodies; ATI; antibodies to infliximab; CD; Crohn's disease; CI; confidence interval; CRP; C-reactive protein;
Original ResearchFull Report: Clinical-Alimentary TractCombination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Keywords: Tumor Necrosis Factor Inhibitors; Purine Antimetabolites; Biologic Treatment; AEs; adverse events; ATI; antibodies to infliximab; AZA; azathioprine; CI; confidence interval; CS; corticosteroid; IBDQ; Inflammatory Bowel Disease Questionnaire; IFX; inflixim
Original ResearchFull Report: Clinical-Alimentary TractAssociation Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Keywords: Anti-Tumor Necrosis Factor; Monoclonal Antibody; Pharmacokinetics; Inflammatory Bowel Disease; ACT-1; Active Ulcerative Colitis Trial 1; ACT-2; Active Ulcerative Colitis Trial 2; ATI; antibodies to infliximab; AUC; area under the curve; CI; confidence i
Track Orientation Density Imaging (TODI) and Track Orientation Distribution (TOD) based tractography
Keywords: ACT; anatomically-constrained tractography; AFD; apparent fiber density; APM; average pathlength map; ATI; angular track imaging; CB; cingulum bundle; CNR; contrast-to-noise ratio; CSD; constrained spherical deconvolution; DEC; directionally-encoded color
GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes
Keywords: GuÃas de Práctica ClÃnica; Diabetes mellitus; Enfermedad cardiovascular; Intolerancia a la glucosa; Manejo del paciente; Prevención; EpidemiologÃa; Pronóstico; Diagnóstico; Factores de riesgo; Tratamiento farmacológico; Intervenciones coronarias;
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Keywords: Anti-TNF Agent; Decision Analysis; Failed Therapy; Algorithm; ADA; adalimumab; ATI; antibodies to infliximab; CT; computed tomography; ICER; incremental cost-effectiveness ratio; IFX; infliximab; QALY; quality-adjusted life-year; TNF; tumor necrosis facto
Long-Term Impact of Laparoscopic Cyst Decortication on Renal Function, Hypertension and Pain Control in Patients with Autosomal Dominant Polycystic Kidney Disease
Keywords: polycystic kidney, autosomal dominant; laparoscopy; ADPKD; adult dominant polycystic kidney disease; ATI; antihypertensive therapeutic index; BP; blood pressure; CKD; chronic kidney disease; CrCl; creatinine clearance; eGFR; estimated glomerular filtratio
Analysis of gene expression profiles in alveolar epithelial type II-like cells differentiated from human alveolar epithelial progenitor cells
Keywords: ABCA3; ATP-binding cassette, sub-family A (ABC1), member 3; AEPC; alveolar epithelial progenitor cell; ATI; alveolar epithelial type I; ATII; alveolar epithelial type II; CDH1; cadherin 1, type 1; C/EBP; CCAAT/enhancer-binding protein; CEBPD; CCAAT/enhanc
A Crohn's Disease Patient Who Does Not Respond to Infliximab: What Is Next?
Keywords: ATI; antibodies to infliximab; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CMV; cytomegalovirus; CRP; C-reactive protein; PML; progressive multifocal leukoencephalopathy; TNF; tumor necrosis factor;
The role of substituent on the aromaticity variation of mono- and di-substituted aza analogs of indole
Keywords: FLU; ATI; Indole; NRT;
Special ArticleReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Keywords: mAbs; monoclonal antibodies; IFX; infliximab; ADA; adalimumab; CZP; Certolizumab pegol; PNR; primary non response to anti-TNF agent; LOR; loss of response to anti-TNF agent; ATI; antibodies to infliximab; ATA; antibodies to adalimumab; FcγR; Fc gamma rec
Medical Therapy for Refractory Pediatric Crohn's Disease
Keywords: ATI; human antibody to infliximab; AZA; azathioprine; CYA; cyclosporine A; IFX; infliximab; 6-MP; 6-mercaptopurine; MTX; methotrexate; PML; progressive multifocal leukoencephalopathy; RA; rheumatoid arthritis; TNF; tumor necrosis factor;
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
Keywords: ATI; antibodies to infliximab; AZA; azathioprine; CI; confidence interval; CIR; controlled ileal release; ECCDS; European Cooperative Crohn's Disease Study; FDA; Food and Drug Administration; MMF; mycophenolate mofetil; 6-MP; 6-mercaptopurine; 6-MMP; 6-me
Species-specific variation of alternative splicing and transcriptional initiation in six eukaryotes
Keywords: AS; alternative splicing; ATI; alternative transcriptional initiation; ASTI; alternative splicing and transcriptional initiation; Evolution; Genome; Transcriptome; Transcriptional isoform;